These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 7374415)

  • 121. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
    Ratzmann ML; Rjasanowski I; Bruns W; Ratzmann KP
    Exp Clin Endocrinol; 1983 Aug; 82(2):216-21. PubMed ID: 6354731
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Drug treatment of hyperlipoproteinaemia.
    Romics L
    Ther Hung; 1983; 31(4):152-60. PubMed ID: 6400456
    [No Abstract]   [Full Text] [Related]  

  • 123. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
    Freyberger H; Schifferdecker E; Schatz H
    Med Klin (Munich); 1994 Nov; 89(11):594-7, 633. PubMed ID: 7815987
    [TBL] [Abstract][Full Text] [Related]  

  • 124. [Therapy with Progressin retard. experimental studies on metabolism].
    Hammerl H; Kränzl C; Nebosis G; Pichler O; Studlar M
    Munch Med Wochenschr; 1971 Aug; 113(33):1112-5. PubMed ID: 5109479
    [No Abstract]   [Full Text] [Related]  

  • 125. Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings.
    Fletcher A; Alkjaersig N; Schonfeld G; Witztum J
    Arteriosclerosis; 1981; 1(3):202-9. PubMed ID: 7295193
    [TBL] [Abstract][Full Text] [Related]  

  • 126. The effect of I.V. glucagon administration on selected metabolic parameters in patients with type IIa, IIb and IV primary hyperlipoproteinaemia.
    Andĕl M; Brodan V; Kucerová L; Brodanová M
    Acta Univ Carol Med (Praha); 1980; 26(5-6):271-92. PubMed ID: 7347126
    [No Abstract]   [Full Text] [Related]  

  • 127. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IV].
    Chwistecki K; Mrukowicz M; Kopel E
    Wiad Lek; 1985 Apr; 38(7):490-4. PubMed ID: 4013323
    [No Abstract]   [Full Text] [Related]  

  • 128. Therapy of the hyperlipoproteinemias.
    Bagdade JD
    Acta Diabetol Lat; 1972 Dec; 9 Suppl 2():98-110. PubMed ID: 4605376
    [No Abstract]   [Full Text] [Related]  

  • 129. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 130. [Hyperlipoproteinemia in diabetes mellitus].
    Slavina LS; Mazovetskiĭ AG; Negovskaia AV; Romanovskaia GA
    Probl Endokrinol (Mosk); 1981; 27(1):36-9. PubMed ID: 7232348
    [TBL] [Abstract][Full Text] [Related]  

  • 131. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IIB and IV].
    Chwistecki K; Mrukowicz M; Kopel E
    Przegl Lek; 1984; 41(9):581-6. PubMed ID: 6393227
    [No Abstract]   [Full Text] [Related]  

  • 132. [Pharmacology of probucol. I].
    Donatelli L
    Clin Ter; 1984 Mar; 108(5):367-88. PubMed ID: 6232074
    [No Abstract]   [Full Text] [Related]  

  • 133. [Arteriosclerosis--nicotinic acid therapy. 10. Combination therapy in hyperlipemia].
    Hansen PF
    Lakartidningen; 1971 Apr; 68(15):1769-72. PubMed ID: 5577252
    [No Abstract]   [Full Text] [Related]  

  • 134. [Effect of phenofibrate on serum cholesterol and triglyceride concentration in patients with primary hyperlipoproteinemia].
    Cieślicka T; Paradowski S
    Pol Arch Med Wewn; 1983; 70(5-6):223-9. PubMed ID: 6677885
    [No Abstract]   [Full Text] [Related]  

  • 135. [Is Etolip suitable for treatment of various types of hyperlipoproteinemias?].
    Kollár J; Rozdobud'ková V; Koprovicová J; Rajnová E; Seiler J
    Vnitr Lek; 1991 May; 37(5):470-8. PubMed ID: 1842145
    [TBL] [Abstract][Full Text] [Related]  

  • 136. The influence of a no-sugar diet on the composition of VLDL-fraction in patients with idiopathic hyperlipoprotenemia of type IIb and IV.
    Cybulska B; Naruszewicz M; Kłosiewicz-Latoszek L; Szostak WB; Chotkowska E
    Mater Med Pol; 1980; 12(4):286-92. PubMed ID: 7266054
    [No Abstract]   [Full Text] [Related]  

  • 137. Mechanism of the hypolipemic effect of clofibrate in glucose-fed men.
    Wolfe BM; Ahuja SP; Marliss EB
    Metabolism; 1980 Mar; 29(3):279-88. PubMed ID: 7374441
    [No Abstract]   [Full Text] [Related]  

  • 138. Increased level of the complement C3 protein in endogenous hypertriglyceridemia.
    Uza G; Cristea A; Cucuianu MP
    J Clin Lab Immunol; 1982 Jun; 8(2):101-5. PubMed ID: 7108936
    [TBL] [Abstract][Full Text] [Related]  

  • 139. [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
    Mertz DP
    Fortschr Med; 1980 Dec; 98(45):1761-6. PubMed ID: 7461569
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Nicotinic acid for the treatment of hyperlipoproteinemia.
    Drood JM; Zimetbaum PJ; Frishman WH
    J Clin Pharmacol; 1991 Jul; 31(7):641-50. PubMed ID: 1894760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.